Journal of Ovarian Research: Thailandepsins are new small molecule class I HDAC inhibitors with potentcytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy

Thailandepsins are new small molecule class I HDAC inhibitors with potentcytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy

 Abstract
Background
New treatment strategies are emerging to target DNA damage response pathways in ovarian cancer. Our group has previously shown that the class I biased HDAC inhibitor romidepsin (FK228) induces DNA damage response and has potent cytotoxic effects in ovarian cancer cells. Here, we investigated newly discovered HDAC inhibitors, thailandepsin A (TDP-A) and thailandepsin B (TDP-B), to determine the effects on cell viability, apoptosis and DNA damage response in ovarian cancer cells......